Pfizer Quick Ratio 2010-2023 | PFE
Historical quick ratio values for Pfizer (PFE) over the last 10 years.
| Pfizer Quick Ratio Historical Data |
| Date |
Current Assets - Inventory |
Current Liabilities |
Quick Ratio |
| 2023-12-31 |
$33.14B |
$47.79B |
0.69 |
| 2023-09-30 |
$63.81B |
$31.14B |
2.05 |
| 2023-06-30 |
$63.04B |
$34.65B |
1.82 |
| 2023-03-31 |
$40.54B |
$36.56B |
1.11 |
| 2022-12-31 |
$42.28B |
$42.14B |
1.00 |
| 2022-09-30 |
$60.89B |
$44.31B |
1.37 |
| 2022-06-30 |
$57.01B |
$47.41B |
1.20 |
| 2022-03-31 |
$44.44B |
$39.27B |
1.13 |
| 2021-12-31 |
$50.63B |
$42.67B |
1.19 |
| 2021-09-30 |
$49.26B |
$41.80B |
1.18 |
| 2021-06-30 |
$39.87B |
$35.66B |
1.12 |
| 2021-03-31 |
$31.04B |
$26.65B |
1.17 |
| 2020-12-31 |
$27.05B |
$25.92B |
1.04 |
| 2020-09-30 |
$38.44B |
$34.15B |
1.13 |
| 2020-06-30 |
$37.86B |
$32.72B |
1.16 |
| 2020-03-31 |
$26.32B |
$33.89B |
0.78 |
| 2019-12-31 |
$25.74B |
$37.30B |
0.69 |
| 2019-09-30 |
$25.24B |
$36.97B |
0.68 |
| 2019-06-30 |
$38.84B |
$32.03B |
1.21 |
| 2019-03-31 |
$37.26B |
$29.42B |
1.27 |
| 2018-12-31 |
$42.42B |
$31.86B |
1.33 |
| 2018-09-30 |
$33.40B |
$29.01B |
1.15 |
| 2018-06-30 |
$29.23B |
$32.16B |
0.91 |
| 2018-03-31 |
$26.69B |
$27.37B |
0.98 |
| 2017-12-31 |
$33.56B |
$30.43B |
1.10 |
| 2017-09-30 |
$32.37B |
$28.22B |
1.15 |
| 2017-06-30 |
$28.80B |
$27.18B |
1.06 |
| 2017-03-31 |
$28.46B |
$24.86B |
1.15 |
| 2016-12-31 |
$32.17B |
$31.12B |
1.03 |
| 2016-09-30 |
$30.99B |
$34.76B |
0.89 |
| 2016-06-30 |
$36.23B |
$32.10B |
1.13 |
| 2016-03-31 |
$33.72B |
$28.74B |
1.17 |
| 2015-12-31 |
$36.29B |
$29.40B |
1.23 |
| 2015-09-30 |
$37.32B |
$27.85B |
1.34 |
| 2015-06-30 |
$45.92B |
$24.14B |
1.90 |
| 2015-03-31 |
$43.66B |
$20.22B |
2.16 |
| 2014-12-31 |
$49.93B |
$21.59B |
2.31 |
| 2014-09-30 |
$50.63B |
$19.92B |
2.54 |
| 2014-06-30 |
$52.04B |
$21.94B |
2.37 |
| 2014-03-31 |
$51.73B |
$24.79B |
2.09 |
| 2013-12-31 |
$50.08B |
$23.37B |
2.14 |
| 2013-09-30 |
$53.02B |
$20.37B |
2.60 |
| 2013-06-30 |
$55.15B |
$23.45B |
2.35 |
| 2013-03-31 |
$57.73B |
$27.54B |
2.10 |
| 2012-12-31 |
$58.76B |
$29.19B |
2.01 |
| 2012-09-30 |
$49.61B |
$29.13B |
1.70 |
| 2012-06-30 |
$51.76B |
$30.80B |
1.68 |
| 2012-03-31 |
$47.67B |
$27.09B |
1.76 |
| 2011-12-31 |
$54.21B |
$28.91B |
1.88 |
| 2011-09-30 |
$54.31B |
$27.86B |
1.95 |
| 2011-06-30 |
$51.89B |
$30.47B |
1.70 |
| 2011-03-31 |
$49.78B |
$29.17B |
1.71 |
| 2010-12-31 |
$52.74B |
$28.64B |
1.84 |
| 2010-09-30 |
$45.32B |
$24.17B |
1.88 |
| 2010-06-30 |
$41.59B |
$24.68B |
1.69 |
| 2010-03-31 |
$39.78B |
$25.92B |
1.54 |
| 2009-12-31 |
$49.27B |
$37.23B |
1.32 |
| 2009-09-30 |
$68.73B |
$23.99B |
2.87 |
| 2009-06-30 |
$66.56B |
$26.11B |
2.55 |
| 2009-03-31 |
$49.80B |
$23.34B |
2.13 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$148.755B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
